FindTrial
Sign In

A pilot of study of effects of a daily foods containing plant extracts in patients with mild cognitive impairment due to Alzheimer's disease

A pilot study of the effects of a daily foods containing plant extracts in the patients with mild cognitive impairment due to Alzheimer's disease - A pilot study of the effects of a daily foods containing plant extracts in the patients with mild cognitive impairment due to Alzheimer's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000052043
Enrollment
15
Registered
2023-08-29
Start date
2023-08-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MCI

Interventions

Oral ingestion of the test product with a plant extract (2 capsules per a day
16 weeks)

Sponsors

Kanagawa Dental University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who diagnosed with Alzheimer's disease (AD) in Yokohama Shintoshi Neurosurgical Hospital (2) Patients who are MCI cognitive impairment with CDR 0.5 or less, and FAST stage 2 or 3 (3) An adult males and females from 45 to 90 years of age, and have no comorbidity or history of malignancies, serious liver disease, or other serious internal disorder (4) Patients who participate in this study with a verbal and written informed consent. (5) Patients who can take 2 capsules of turmeric product per day

Exclusion criteria

Exclusion criteria: (1) Patients who are Alzheimer's disease (AD) with CDR 1 or over, and FAST stage 4 or over (2) Patients who are Mild Cognitive Impairment (MCI) not due to AD (3) An adult males and females under 45 or over 90 years of age, and have comorbidity or history of malignancies, serious liver disease, or other serious internal disorder (4) Patients who take drugs, quasi-drug or health food on a daily basis, such as Docosahexaenoic Acid (DHA), eicosapentaenoic acid (EPA), Ginkgo biloba extract, linseed oil, tocotrienols, tocopherols, astaxanthin, Gamma Amino Butyric Acid (GABA), phosphatidylserine, and plasmalogen. (5) Patients who have extremely irregular dietary habits (7) Patients who have excessive alcohol-drinking or (8) Patients who are smoker (9) Patients who have soy allergy (10) Patients who have plan to participate in other trial during scheduled period in this trial (11) Patients judged as unsuitable for the study by the investigators

Design outcomes

Primary

MeasureTime frame
At 0, 8, 16 weeks in the intervention (1) Amyloid-beta-related composit marker in blood assessed by Amyloid MS CL AXIMA (2) Trail Making Test-A/B (3) MoCA-J (4) NouKNOW—

Secondary

MeasureTime frame
At 0, 8, 16 weeks in the intervention (1) C-reactive protein (CRP) (2) Tumor necrosis factor (TNF)-alpha (3) Brain-derived neurotrophic factor (BDNF)—

Countries

Japan

Contacts

Public ContactRyosuke Saji

House Wellness Foods Corporation Research and Development Institute Material Research Division

ryosuke.saji.hy8@housefoods.co.jp072-778-1127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026